The branded generics and OTC product portfolio of PharmaSwiss is expected to strengthen Valeant’s presence in the region.
Reportedly, the senior management team of PharmaSwiss will remain with Valeant Pharma, including both the founder-partners, as well as Pavel Mirovsky, CEO of PharmaSwiss.
Valeant Pharma business in Central Europe will be combined under the PharmaSwiss corporate structure, based in Zug, Switzerland.
Valeant develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.